CSPC Pharmaceutical Group Limited (HKG:1093)
Hong Kong · Delayed Price · Currency is HKD | Market Cap | 111.01B +102.8% |
| Revenue (ttm) | 28.94B -10.4% |
| Net Income | 4.32B -10.3% |
| EPS | 0.38 -7.8% |
| Shares Out | 11.43B |
| PE Ratio | 25.68 |
| Forward PE | 16.15 |
| Dividend | 0.29 (2.99%) |
| Ex-Dividend Date | Jun 24, 2026 |
| Volume | 101,007,222 |
| Average Volume | 104,625,361 |
| Open | 9.62 |
| Previous Close | 9.62 |
| Day's Range | 9.49 - 9.88 |
| 52-Week Range | 4.63 - 11.63 |
| Beta | 0.89 |
| RSI | 57.60 |
| Earnings Date | Mar 25, 2026 |
About CSPC Pharmaceutical Group
CSPC Pharmaceutical Group Limited, an investment holding company, engages in the manufacture and sale of pharmaceutical products in Mainland China, other Asian regions, Europe, North America, and internationally. It operates through Finished Drugs, Bulk Products, and Functional Food and Others segments. The company provides NBP soft capsules and injections for acute ischemic stroke; Oulaining capsules and injections to treat mild to moderate memory and mental impairment; Enxi to treat adult idiopathic Parkinson’s disease; Duomeisu for lymphoma,... [Read more]
Financial Performance
In 2025, CSPC Pharmaceutical Group's revenue was 26.01 billion, a decrease of -10.35% compared to the previous year's 29.01 billion. Earnings were 3.88 billion, a decrease of -10.30%.
Financial numbers in CNY Financial StatementsNews
AstraZeneca Strikes Multibillion-Dollar Obesity Deal With China's CSPC
The agreement to gain rights outside of China to a portfolio of experimental obesity and diabetes drugs could be valued at billions of dollars.
China's CSPC Pharmaceutical inks deal with AstraZeneca for weight loss therapy
CSPC Pharmaceutical Group said on Friday it had entered an agreement with UK drugmaker AstraZeneca for the development of innovative long-acting peptide medicines for obesity and weight-related condit...